Table 1.

Clinical and biologic characteristics of the severe acute respiratory syndrome coronavirus 2–infected group

CharacteristicResult
Clinical
 Age (yr) mean (min; max) (n=16)68.2 (49; 95)
 Women % (n=16)31.3
 Body mass index (kg/m2) mean (min; max) (n=16)30.7 (20.7; 39.6)
Medical history
 Hypertension % (n=16)62.5
 Diabetes % (n=16)56.3
 CKD % (n=14)42.9
 Active cancer or history % (n=14)12.5
 Cardiovascular disease % (n=16)43.8
 Immunocompromise status % (n=16)25
 Asthma/COPD % (n=16)0
 Nonsmoker % (n=14)78.6
 RAAS inhibitors drugs % (n=16)50
 Hydroxychloroquine used during hospitalization % (n=16)87.5
 Contrast products injection during hospitalization % (n=16)18.8
 Antiplatelets used before hospitalization % (n=16)43.8
 Anticoagulation during hospitalization % (n=16)75
Hospital stay length (d) median (IQR) (n=16)14 (7.5–22.5)
Severity
 ICU admission % (n=16)62.5
 Thorax CT scanner staging % (n=16)
  Minor (<10%)18.8
  Mild (10%–50%)37.5
  Severe (>50%)43.7
 Renal severity
  AKI % (n=16)62.5
  CVVH initiation during hospitalization % (n=16)18.5
  30% decrease of eGFR during hospitalization % (n=16)50
  Proteinuria at D0 >500 mg/g of urine creatinine % (n=15)53.3
  Hematuria at D0 % (n=13)53.8
Biologic
 ABO group % (n=14)
  A–B–AB–O64.3–14.3–0 –21.4
 Lymphocytes at D0 (/mm3) median (IQR) (n=16)720 (520–1440)
 Lymphocytes at end of hospitalization (/mm3) median (IQR) (n=15)970 (530–1280)a
 Platelet at D0 (×1000/mm3) mean (min; max) (n=16)211.4 (79; 417)
 Platelet at end of hospitalization (×1000/mm3) mean (min; max) (n=15)230.3 (26; 457)a
 C-reactive protein at D0 (mg/L) mean (min; max) (n=16)166.5 (4.4; 382.4)
 C-reactive protein at end of hospitalization (mg/L) mean (min; max) (n=15)195.5 (3.8; 311.9)a
 Fibrinogen (g/L) at D0 median (IQR) (n=16)7.18 (4.83–7.72)
 Fibrinogen (g/L) at end of hospitalization, median (IQR) (n=15)6.96 (5.01; 7.86)a
 Procalcitonin at D0 (µg/L) median (IQR) (n=13)0.33 (0.16–0.83)
 D-dimer at D0 (µg/L) mean (min; max) (n=11)1309.5 (329; 2991)
 LDH at D0 (U/L) mean (min; max) (n=16)532.8 (195; 881)
 CPK at D0 (U/L) median (IQR) (n=16)286.5 (181.5–445)
 eGFR (before hospitalization) (n=13)
  60–90 ml/min per 1,73 m2 %46.2
  <60ml/min per 1,73 m2 %23.1
  <30 ml/min per 1,73 m2 %0
 Serum creatinine at D0 (mg/dl) median (IQR) (n=16)1.07 (0.83–1.27)
 Serum creatinine at end of hospitalization (mg/dl) median (IQR) (n=16)0.96 (0.68–1.62)a
 Potassium at D0 (mmol/L) mean (min; max) (n=16)4.16 (3.55; 4.63)
 Proteinuria at D0 (mg/g of urine creatinine), median (IQR) (n=15) proteinuria at D7 (mg/g of urine creatinine) median (IQR) (n=10)580 (320–830)
650 (400–1520)b
Delay biopsy (n=16)
 <60 (min) %62.5
 60–120 (min) %12.5
 120–180 (min) %25
  • COPD, chronic obstructive pulmonary disease; D0, day 0 of hospital admission; D7, day 7 after hospital admission; RAAS, renin angiotensin aldosterone system; IQR, interquartile range; ICU, intensive care unit; CT, computed tomography; CVVH, continuous venovenous hemofiltration; LDH, lactate dehydrogenase; CPK, creatinine phospho-kinase.

  • a No statistical difference observed between D0 and the end of hospitalization.

  • b No statistical difference observed between D0 and D7.